Bristol Myers Squibbs profits and Rosy Outlook On Thursday, persistent problems for the stock have not solved. But it was enough for the time being. The turnover in the first quarter, which ended on March 31, fell 6% to 11.2 billion US dollars, but according to LSEG it was estimates of 10.7 billion US dollars. The adapted result per share of USD $ 1.49 exceeded the expectations of $ 1.49. The company reported a loss in the first quarter of last year. BMY YTD Mountain Bristol Myers on warehouse from year to year. While the mostly lower Thursday over 48 US dollars per each are over 48 US dollars, Bristol Myers' shares in April in April in April in April in April in April and some disappointing news about the pipeline lost around 20%. We are leading our holding equivalent 2 rating in March when we gained profits at around $ 62 per share-and lowered our price target from USD $ 60. Conclusion Bristol Myers has a harder road to prove that it can affect some of its older medication through an impending generic competition. And the failed study of this week for a new schizophrenia treatment, which is Cobenfy, is the reason. It increases the yardstick for the execution of Cobenfy for both the currently approved state and for the future clinical experimental instructions for new uses of the drug such as Alzheimer's disease psychosis. Bristol Myers' results in the first quarter on Thursday were solid on the face, since sales, income and gross margins met the expectations. In two of the company's older medicines, however, it was deeper into the numbers -blood -thinning eliquis and blood cancer therapy Revlimide -that complained about a good part of the top line. This helps to explain the subdued market reaction to the quarter, and a similar dynamic with Bristol Myers' increased sales and profit consultations by Bristol Myers. Is it frustrating that weaker Revlimid numbers are violated the share last time he reported profits and now shaken off the expected results of the drug? Yes. But the disappointing Cobenfy study -in addition to a recently failed study to expand the use of heart -drug -Camzyos, so as not to mention anything about tariff uncertainties, has understandably created a less forgiving backdrop. Bristol Myers Squibb Why we own it: The company's new schizophrenia treatment has great sales potential, even though it stays in the early inner. Bristol Myers has important products such as blood loss prevention medication and lung cancer therapy OPDIVO, which will emerge from patent in the coming years. However, we believe that its portfolio of growth medication, including Cobenfy, can help control this patent cliff. Initiation: November 25, 2024 Last purchase date: February 10, 2025 competitors: Abbvie, Pfizer, Amgen, Johnson & Johnson and Johnson and Merck, as Jim Cramer explained on Thursday morning, we have not lost the full confidence in Bristol Myers's ability. At the current prices, the dividend yield of the share of 5% is also attractive, and the evaluation with less than 8 -fold forward gains is not demanding. Nevertheless, the way to victory and the sensible stocks have become more difficult. The comment investors on Thursday were on Cobenfy-the core of the stock work of the club laser-oriented after the new schizophrenia medication in a study in which the effectiveness was examined as an add-on therapy for the disorder did not meet expectations. This put the stock under pressure at the session on Wednesday and missed a wide rally over the market. Cobenfy is the key to Bristol Myers's plan to navigate after several “Legacy” drugs such as the above -mentioned eliquis and revlimide. Cobenfy received his 14 -billion dollar purchase of Karuna Therapeutics in September 2024, six months after Bristol Myers brought the Coberfy on board. Cobenfy's turnover in the first quarter was, according to Factset, in front of the 17 million US dollars expected by analysts. However, the registered number includes a “gross-net advantage of $ 9 million”, which is associated with discounts and discounts, which makes the beat less significant compared to expectations. CEO Chris Boerner said Bristol Myers was satisfied with the early prescription trends for Cobenfy. “The feedback for patients and doctors is very positive,” he said, adding that “patients observe cognitive advantages”. Despite the setback of add-on test versions, Boerner and other managers on the call had a positive view of the future of Cobenfy. The company continues to focus on Cobenfy as an independent treatment, which corresponds to 70% to 80% of the market, said Boerner. The goal is that Cobenfy is the “basic treatment” there, he said. Adam Lenkowsky, Chief Commercialization Officer of the company, gave a deeper explanation of why the add-on treatment option in its plans was secondary. He said that psychiatrists ideally only want to give their patients one medication. However, he said that the reason why they start taking add-on therapies is an independent treatment for themselves. Bristol Myers wants to open Coberfy in the treatment line so that the doctors consider prescribing them earlier, said Lenkowsky. In a further sign of trust in the medication, Boerner expects Bristol Myers to begin three additional studies in the late stage in the middle of the year, in which Cobenfy's ability to deal with other diseases: (1) Alzheimer's agitation, (2) Alzheimer's recognition impairment and (3) bipolar. Managers said that the setback in add-on schizophrenia does not change their expectations of the other attempts. The guidelines Bristol Myers increased its instructions from 2025 to some important key figures, but the reasons for the revision inlay advantages for foreign exchange explains why the company does not receive much loan. Bristol Myers' sales outlook is now $ 45.8 billion up to $ 46.8 billion, compared to $ 45.5 billion. This reflects an advantage of 500 million US dollars from the exchange rates. The company also expects to better than the expected income from its “Legacy” portfolio of drugs in the first quarter and what the company described in its more important “growth portfolio” as a strong performance. In the first quarter, the growth portfolio recorded a sales experience of 18% and corresponded to about half of the total turnover. According to the yield, the legal portfolio income is expected to decrease between 16% and 18% this year, which is primarily due to the performance of Revlimide. Bristol Myers has retained its total year of 37%. The new adjusted EPS instruction from 6.70 to 7 US dollars rose by 15 cents at both ends in the area. The company also takes into account 70 million US dollars more in license fees and interest income than previously expected. In addition, the guidelines make up existing tariffs for US products imported into China, but not the pharmaceutical pharmaceutical tariffs threatened by the Trump government. It is not surprising that managers were cared for with questions about tariffs about the call for profits, and their overarching message was basically that the company in its production network has a lot of flexibility to react, and they are looking for ways to optimize it with tariffs. Bristol Myers is significantly represented in the United States, but is not excessively dependent on a country for its supply chain, the managers said. “We will continue to deal with the administration to ensure that ultimately everything that comes down, well thought out and in terms of the way we go forward, is well thought out and aware,” said Boerner. One last thing that has to be emphasized from the call was the discussion about business development, which was often shortened by managers to only “BD”. This includes potential acquisitions or partnerships to drugs that represent a different level in order to complete the patent failures. Boerner said Bristol Myers followed “active opportunities” that the company's growth profile can increase. “With our renewed organizational agility and balance in a solid position, we have the flexibility to act determined when we find the right possibilities,” he said. (Jim Cramers Charitible Trust is boring. Here you will find a full list of stocks.) As a subscriber of the CNBC Investing Club with Jim Cramer, you will receive a trading warning warning before Jim retreating. Jim waits for 45 minutes after he has sent a trade warning before bought or selling a share in the portfolio of his non -profit trust. When Jim spoke about a share on CNBC television, he waits 72 hours after the output of the trade war before he executed the trade. The above -mentioned investment club information is subject to our general terms and conditions and data protection guidelines together with our disclaimer. There is no trust or strategy or is created due to its receipt of information provided in connection with the Investing Club. It is not guaranteed to be a specific result or profit.
The logo of the pharmaceutical company Bristol-myers Squibb (BMS) can be seen on August 29, 2024 in Munich (Bavaria) on the facade of the company's Munich headquarters.
Matthias Balk | Image Allianz | Getty pictures
Bristol Myers SquibbThe result of the profits and the Rosy Outlook on Thursday did not solve continuing problems for the stock. But it was enough for the time being.
